Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

VolitionRX Ltd (VNRX)

Total paid for Promotions this month: $0
E-mails this Month: 1
Estimated Volume Generated: $0
Research Report on VNRX: Click to see
* The information presented is based on information for Sep , 2014
HOME ABOUT US TRADE IDEAS PENNY STOCK ARTICLES DAILY NEWS Call Us: 561-807-6350   |   Email Us: info@smallcapstockplays.com Small Cap Investors, Last weeks Spotlight VolitionRx Limited (OTCQB: VNRX) has been testing the $5 dollar range up 25%. VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. ...read more
Promoter: SmallCapStockPlays Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
VNRX Unknown compensation UNKNOWN
Max Profit: 1.59 % Gain at close: Pending
  VolitionRx Ltd. (VNRX) VolitionRx Ltd. is a life sciences company focused on bringing to market its inexpensive, accurate, and scalable cancer detection blood tests. The company intends to use its NuQ® suite of products to fill a looming void in cancer diagnostic testing, for which there currently is only one blood test in common clinical use.     View The Full Company Profile Armco Metals Holdings, Inc. ...read more
Promoter: Tip.us Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
VNRX $26,050 UNKNOWN
Max Profit: 0.00 % Gain at close: Pending
  VolitionRx Ltd. (VNRX) VolitionRx Ltd. is a life sciences company focused on bringing to market its inexpensive, accurate, and scalable cancer detection blood tests. The company intends to use its NuQR suite of products to fill a looming void in cancer diagnostic testing, for which there currently is only one blood test in common clinical use.  View The Full Company Profile Actinium Pharmaceuticals, Inc. (ATNM) Boston ...read more
Promoter: Tip.us Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
VNRX $26,050 UNKNOWN
Max Profit: 3.23 % Gain at close: Pending
It Gets $5M Milestone Payment, Eligible to Receive Up to an Additional $95M in Payments   Cell Therapeutics, Inc. (CTIC)   CTIC reported that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of a sales milestone for TRISENOXR) (arsenic trioxide).   TRISENOX was acquired from CTIC by Cephalon, Inc., which was subsequently acquired by Teva.   The milestone was paid ...read more
Promoter: Crweselect.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
VNRX Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: Pending
It Gets $5M Milestone Payment, Eligible to Receive Up to an Additional $95M in Payments (Mailing list information, including unsubscription instructions, is located at the end of this message.)   Cell Therapeutics, Inc. (CTIC)   CTIC reported that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of a sales milestone for TRISENOXR) (arsenic trioxide).   TRISENOX was acquired ...read more
Promoter: pennyomega.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
VNRX Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: Pending
It Gets $5M Milestone Payment, Eligible to Receive Up to an Additional $95M in Payments   Cell Therapeutics, Inc. (CTIC)   CTIC reported that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of a sales milestone for TRISENOXR) (arsenic trioxide).   TRISENOX was acquired from CTIC by Cephalon, Inc., which was subsequently acquired by Teva.   The milestone was paid ...read more
Promoter: Crwefinance.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
VNRX Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: Pending
Video not found or You must install the Flash Plugin for your Browser in order to view this movie